A Phase II Study to Evaluate the Efficacy and Safety of GT90001 in Combination with Nivolumab as a Second-line Treatment in Subjects with Advanced Hepatocellular Carcinoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Hepatocellular Carcinoma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Subjects must have confirmed diagnosis of aHCC (locally advanced or metastatic hepatocellular carcinoma) by radiography, histology and/or cytology, not eligible for surgical and/or locoregional therapies; or progressive disease after surgical and/or locoregional therapies (fibrolamellar, sarcomatoid HCC and mixed hepatocellular / cholangiocarcinoma subtypes are not eligible).
    2. Have Barcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy.
    3. Cohort B: Have documented disease progression after or intolerance to first line treatment of immune checkpoint inhibitors such as Atezolizumab plus Bevacizumab.

You may not be eligible for this study if the following are true:

    1. Presence of tumor thrombus involving main trunk of portal vein (Vp4), inferior vena cava, cardiac involvement of HCC.
    2. Subjects with untreated or incompletely treated varices with bleeding or high risk for bleeding.
    3. History of encephalopathy.



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.